Trial · NCT07218380
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events related to vepugratinib in combination with EV and pembrolizumab | From baseline up to 90 months | |
| Primary | Safety Lead-in: Overall Response Rate (ORR) | From baseline up to 90 months | ORR by Investigator Assessment. |
| Primary | Progression-free Survival (PFS) | Baseline to Study Completion (estimated as 6 years) | PFS by blinded independent committee review (BICR). |
| Secondary | Safety Lead-in: Disease Control Rate (DCR) | From baseline up to the end of Cycle 2 (each Cycle is 21 days) | DCR by investigator assessment. |
| Secondary | Safety Lead-in: Time to Response (TTR) | From baseline up to 90 months | TTR by investigator assessment. |
| Secondary | Overall Survival (OS) | Baseline to Study Completion (estimated as 6 years) | |
| Secondary | Objective Response Rate (ORR) by BICR | Baseline to Study Completion (estimated as 6 years) | |
| Secondary | Duration of Response (DoR) | Baseline to Study Completion (estimated as 6 years) | DOR by BICR. |
| Secondary | Progression-free Survival (PFS) | Baseline to Study Completion (estimated as 6 years) | PFS by investigator assessment. |
| Secondary | Objective Response Rate (ORR) | Baseline to Study Completion (estimated as 6 years) | Percentage of Participants who Achieve a Best Overall Response (BOR) of Complete Response (CR) or Partial Response (PR)ORR by investigator assessment |
| Secondary | Duration of Response (DOR) | Baseline to Study Completion (estimated as 6 years) | DOR by investigator assessment. |
| Secondary | Progression-free Survival 2 (PFS2) | Baseline to Study Completion (estimated as 6 years) | PFS2 by investigator assessment. |
| Secondary | Plasma Concentrations of Vepugratinib | Cycle 1 Day 1 to Study completion (estimated as 90 months) | PK samples are to be drawn every odd cycle while participant on study. |
| Secondary | Change from Baseline in Global Health Status/Quality of Life (QOL) and Physical Function Measured by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) | Baseline to Study Completion (estimated as 6 years) | The EORTC QLQ-C30 is a validated self-reported general cancer questionnaire consisting of 30 items with a recall of the past 7 days. Response options range from 1) "very poor" to 7) "excellent." Higher scores represent better overall HRQoL. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07218380/registered